Epidemiology: Open Access
Open Access

Abstract

Chagas disease is anthropozoonosis caused by the protozoan Trypanosome cruzi ( T. cruzi ), mainly transmitted by insect vectors of the Reduviidae family. It is distributed throughout the Americas. It is estimated that in Brazil 25 million people live in risk areas and five million are infected. Creatinephosphokinase MB fraction has long been considered a marker for the diagnosis of myocardial injury, caused by this parasite. This study aims to evaluate the prognostic value in laboratory scope of CK- MB in patients diagnosed with Trypanossome cruzi infection. Transversal study where we selected 24 patients treated at health centers in Belem - Pará - Brazil , all with clinical signs and symptoms of infection by the parasite , infection confirmed by testing Enzyme Linked Immuno Sorbent Assay ( ELISA) and testing haemagglutination Inhibition ( HAI) . Was used for measurements of serum CK- MB in the method of Enzyme linked fluorescent assay ( ELFA ) by bioMérieux®. In 41.6 % of cases the CK- MB remained at normal levels < 5.0 μg / ml and in 58.4 % CK -MB is altered > 5.0ug / ml. In patients where the CKMB was changed mainly seemed to be a direct relation of infection time, since this marker appears to have more sensitivity when the heart muscle is already showing necrosis, thus demonstrating a more advanced disease compared to patients that show normal rates. Creatinephosphokinase MB fraction apparently not presented with a good marker for the early diagnosis of myocardial injury.

Biography